Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01482520|
Recruitment Status : Completed
First Posted : November 30, 2011
Last Update Posted : May 14, 2014
All Hepatocellular carcinoma and Renal cell carcinoma patients who receive molecular targeted therapy will be candidates for the study.
No additional treatment or intervention will be conducted except for blood sampling that will be limited to one time only.
Blood samples (10 cc in volume) will be collected from all study participants once they provided written informed consent form. DNA will be extracted from peripheral blood samples using DNA isolation kit.
|Condition or disease|
|Hepatocellular Carcinoma Renal Cell Carcinoma|
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma|
|Study Start Date :||August 2008|
|Actual Primary Completion Date :||September 2013|
|Actual Study Completion Date :||October 2013|
|Renal cell carcinoma|
|Hepatocellular carcinoma patients|
- Genotypes [ Time Frame: 36months ]
To define genotypes of HCC and RCC patients who will likely to response to molecular targeted therapy.
To define genotypes associated with adverse events from molecular targeted.
To identify genotypes which will predict survival or disease-free survival following molecular targeted therapy.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01482520
|Korea, Republic of|
|Samsung Medical Center|
|Seoul, Korea, Republic of|